Want to see JP:4569 full AI Analyst Report?
4569 Stock Chart & Stats
¥1181.00
-¥69.00(-5.70%)
At close: 4:00 PM EDT
¥1181.00
-¥69.00(-5.70%)
Day’s Range― - ―
52-Week Range¥1,052.00 - ¥1,725.00
Previous CloseN/A
Volume266.10K
Average Volume (3M)258.36K
Market Cap
¥59.38B
Enterprise Value¥72.70K
Total Cash (Recent Filing)¥16.95B
Total Debt (Recent Filing)¥23.24B
Price to Earnings (P/E)29.8
Beta0.49
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.05%
Share Statistics
EPS (TTM)37.80
Shares Outstanding59,945,640
10 Day Avg. Volume183,430
30 Day Avg. Volume258,363
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)0.66
Price to Sales (P/S)0.75
P/FCF Ratio37.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)30.7
Revenue Forecast (FY)¥123.03B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and continued equity growth provide financial flexibility to absorb earnings volatility, fund pharmaceutical development, and maintain operations without excessive dependence on external borrowing.
Resilient Revenue BaseThe multi-year revenue trend indicates an established commercial platform and recurring demand for the company’s prescription medicines. This provides a foundation for recovery if product volumes, market share, or portfolio mix improve.
FY2026 Cash Flow ReboundThe return to positive free cash flow and stronger operating cash generation supports ongoing investment in R&D and commercialization. Although consistency remains limited, the latest improvement provides some funding capacity without relying solely on financing.
Bears Say
FY2026 Revenue DeclineThe latest revenue contraction interrupts the prior multi-year upward trend and may indicate weaker prescription demand, product mix pressure, competition, or reimbursement effects. Sustained declines would reduce operating leverage and constrain investment capacity.
Material Margin CompressionSharp compression across gross and net margins demonstrates increased sensitivity to costs, product mix, pricing, or lower sales volume. Persistently weaker profitability could limit returns on R&D and reduce funds available for portfolio renewal.
Volatile Free Cash FlowSeveral years of negative free cash flow followed by only a modest rebound indicate inconsistent cash conversion and possible variability in investment or working-capital needs. This makes long-term funding for development and shareholder distributions less predictable.
KYORIN Pharmaceutical Co.,Ltd. News
4569 FAQ
What was KYORIN Pharmaceutical Co.,Ltd.’s price range in the past 12 months?
KYORIN Pharmaceutical Co.,Ltd. lowest stock price was ¥1052.00 and its highest was ¥1725.00 in the past 12 months.
What is KYORIN Pharmaceutical Co.,Ltd.’s market cap?
KYORIN Pharmaceutical Co.,Ltd.’s market cap is ¥59.38B.
When is KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date?
KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date is Nov 09, 2026 which is in 49 days.
How were KYORIN Pharmaceutical Co.,Ltd.’s earnings last quarter?
KYORIN Pharmaceutical Co.,Ltd. released its earnings results on Jul 30, 2026. The company reported ¥14.35 earnings per share for the quarter.
Is KYORIN Pharmaceutical Co.,Ltd. overvalued?
According to Wall Street analysts KYORIN Pharmaceutical Co.,Ltd.’s price is currently Overvalued.
Does KYORIN Pharmaceutical Co.,Ltd. pay dividends?
KYORIN Pharmaceutical Co.,Ltd. pays a Semiannually dividend of ¥10 which represents an annual dividend yield of 5.05%. See more information on KYORIN Pharmaceutical Co.,Ltd. dividends here
What is KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate?
KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KYORIN Pharmaceutical Co.,Ltd. have?
KYORIN Pharmaceutical Co.,Ltd. has 59,945,640 shares outstanding.
What happened to KYORIN Pharmaceutical Co.,Ltd.’s price movement after its last earnings report?
KYORIN Pharmaceutical Co.,Ltd. reported an EPS of ¥14.35 in its last earnings report. Following the earnings report the stock price went down -0.575%.
Which hedge fund is a major shareholder of KYORIN Pharmaceutical Co.,Ltd.?
Currently, no hedge funds are holding shares in JP:4569
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KYORIN Pharmaceutical Co.,Ltd.
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse therapeutic catalog features medications such as Flutiform for asthma; Desalex, an antiallergic agent; and treatments like Beova, Uritos, and Imidafenacin KYORIN for overactive bladder. The company also offers Lasvic, a quinolone antibacterial; Pentasa for managing ulcerative colitis and Crohn's disease; Nasonex and Kipres for allergic rhinitis; and Mucodyne, a mucoregulating compound. Further pharmaceutical products include Montelukast KM, prescribed for bronchial asthma and allergic rhinitis. Beyond drugs, KYORIN Holdings markets specialized items like the GeneSoC real-time PCR system, disinfectant solutions such as Rubysta and Milton, over-the-counter remedies, diagnostic tools, industrial chemicals, and various reagents and intermediates. The company extends its services to include contract drug manufacturing and actively participates in early-stage research, including identifying and assessing candidate compounds, analyzing competitor technologies, and collecting data from clinical trials.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―